107 filings
Page 2 of 6
8-K
2lwabn3c 6i9f1i61gc8
28 Mar 24
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
4:35pm
8-K
1m1rvo8nxgo
9 Feb 24
Regulation FD Disclosure
7:12am
8-K
a0r9goy6skk0da3wqt
9 Jan 24
Regulation FD Disclosure
7:56am
8-K
z4q49m1yc2 gax
11 Dec 23
Regulation FD Disclosure
7:05am
8-K
5z4r68mdzx
13 Nov 23
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
4:17pm
8-K
3fo5d0vndtf jkfl43
25 Oct 23
Regulation FD Disclosure
9:49am
8-K
kfts5db e26oz
23 Aug 23
ORX750, an oral selective orexin receptor 2 agonist, promotes wakefulness and reduces cataplexy in the orexin/ataxin-3 mouse
6:00pm
8-K
p5g20b
14 Aug 23
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023
7:06am
8-K
mvqke6owo7kp
10 Jul 23
Regulation FD Disclosure
5:00pm
8-K
3drbnp5e2oyoqkei
22 Jun 23
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
kkg5aavxp5k431qyemx9
9 Jun 23
Regulation FD Disclosure
7:10am
DEFA14A
qd54sin
23 May 23
Additional proxy soliciting materials
4:08pm
8-K
47s cj77l3cl
22 May 23
Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B
7:06am
ARS
lium13t
15 May 23
Annual report to shareholders
8:00am
8-K
k6oprtloajwaxz
12 May 23
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023
7:04am